Tanja Spanic

[Tanja Spanic @TanjaSpanic]

New update with longer follow up from POSITIVE trial for young women with HR+ breast cancer 💕
I’m proud to be part of this trial from the very beginning 💕⬇️

[Annals of Oncology @Annals_Oncology]

🆕 Results from the POSITIVE trial with longer term follow-up are now out in @Annals_Oncology

Temporary interruption of endocrine therapy to attempt pregnancy is safe and does not increase the risk of #breastcancer events @AnnPartridgeMD
https://t.co/vyBN0TtPyM

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 First-line camizestrant for emergent ESR1 mutations in advanced breast cancer : Final progression-free survival2 from the phase III SERENA-6 trial.
Presented by François-Clément Bidard MD, PhD🎙️✨ #ASCO26 @OncoAlert #OncoAlertAF

[Sara Tolaney @stolaney1]

Beautiful presentation by @ErikaHamilton9 on HER2CLIMB-05!

Subset analysis of pts with HR+ dz by ET use highlights how critical it is to give ET to our HR+ HER2+ pts

@OncoAlert #ASCO26

[Sara Tolaney @stolaney1]

Important study for q12wk denosumab c/w q4wk--> can give denosumab every 12 wks and have less toxicity and similar benefits

@OncoAlert #ASCO26

[Luca Arecco, MD @Lucarecco]

Published in @Annals_Oncology, the updated results of the #POSITIVE trial reinforce the concept that temporarily discontinuing adjuvant ET to attempt pregnancy is safe and feasible in young pts treated for early breast cancer! @OncoAlert

[Icro Meattini @Icro_Meattini]

Prognostic and predictive impact of baseline gene expression in the NATALEE trial of adjuvant ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early #BreastCancer

Stephen K.L. Chia #ASCO26

@OncoAlert #OncoAlert

[Icro Meattini @Icro_Meattini]

Post-progression treatment analyses of evERA #BreastCancer - A phase III trial of giredestrant + everolimus in patients with ER+, HER2– aBC previously treated with a CDK4/6 inhibitor

Komal L. Jhaveri #ASCO26

@OncoAlert #OncoAlert

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Seems like a good opportunity for a label that is irrespective of line of therapy. Hard to believe a trial in first line vs SOC would have anyone at 'equipoise' and would be mostly taking advantage of artificially limited access. @FDAOncology

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan + pembrolizumab vs
chemotherapy + pembro in participants with previously untreated PD-L1+ metastatic triple-negative breast cancer presented by @stolaney1 ✨🎙️
#ASCO26 @OncoAlert #OncoAlertAF #BreastCancer

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Palbociclib plus tamoxifen + goserelin in women with hormone
receptor-positive, HER2-
negative advanced breast cancer: PATHWAY, an Asian international double-blind
randomized phase 3 trial
Final overall survival analysis.
Yen-Shen Lu 🎙️✨ #ASCO26 @OncoAlert #OncoAlertAF

[Matteo Lambertini, MD PhD @matteolambe]

Data just presented at #ASCO26 by @AndreaDeCensi on efficacy of #BabyTam in particularly post menopausal women with mostly #DCIS are simultaneously published in @JCO_ASCO 👏

Here the link to the full article:
https://t.co/FE8NP4tIs2

@OncoAlert #GallieraHospital @ChampalimaudF

[Hope Rugo @hoperugo]

#asco26 back to back presentations by @stolaney1 and Carlos Barrios Ascent 04 and 03. Efficacy of SG maintained across TROP2 expression, tBRCA status and HER2 exp. In ascent04 interesting trend for better PFS in higher TROP2. @OncoAlert

[Icro Meattini @Icro_Meattini]

ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan vs chemotherapy in participants with previously untreated advanced triple-negative #breastcancer who are not candidates for PD-(L)1 inhibitors

Carlos H. Barrios #ASCO26

@OncoAlert #OncoAlert

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Immunotherapy for Breast Cancer in 2026✨@SDownsCanner 👏🏻 #ASCO26 @OncoAlert #OncoAlertAF #BreastCancer

[Luca Arecco, MD @Lucarecco]

#ASCO26 Science Symposium: A-BRAVE suggests ToDa of avelumab may affect outcomes in high-risk eTNBC.
- AM IO seemed favorable in immune-hot tumors
- PM IO appeared better in immune-cold tumors. Immune-aligned timing was linked to better DDFS/OS.
Congrats @vitti10 and the whole🇮🇹A-BRAVE team!
@OncoAlert

[Tanja Spanic @TanjaSpanic]

Patients are the ultimate stakeholders in cancer research. Key takeaway from @stage4kelly at #ASCO26: every clinical trial should include patient-reported outcomes and quality of life measures. The best clinical trials are designed with patients and include PROs

@OncoAlert

[Icro Meattini @Icro_Meattini]

First results from the OPTIMA phase III randomized non-inferiority trial of test-directed #chemotherapy in patients with high clinical risk ER-positive HER2-negative early #BreastCancer

Robert C. Stein #ASCO26

@OncoAlert #OncoAlert

[OncoAlert @OncoAlert]

A HUGE Round of thanks! The #OncoAlert5k 🚨Continues to Grow year after year, with a lot of new faces but also all the regulars🏃‍♂️

Thank you all of the great support!
WE ARE INDEED ALL OncoAlert!!

@Icro_Meattini @BalazsHalmosMD @alitimumab @MikeSerzanMD @barrosonco @DrVilmaPBarcia @DonjetaZeqa @crisonco @santcancela @golbretas @fedenichetti @crisonco @CathyEngMD @BenWestphalen @OncBrothers @graokane @realbowtiedoc @GaiaGriguolo @COR2EDMedEd @mirrorsmed @amerseburger @DrMirallas @ravikanesvaran @fabioturco92 @salvolarosa @KidneyCancer We Totally missed @to_be_elizabeth @ElisaAgostinett @nataliagandur and @CentralParkWMD @Latinamd @CathyEngMD @LaurenMachos @JooMouta2 @drteplinsky @matteolambe and many more but we look forward to seeing them at the 5k in Madrid🇪🇸 or during OUR HOMECOMING 5k in my HOME of San Antonio Tx🇺🇸for #SABCS26

[Dr Sarah Sammons @drsarahsam]

Dr Piccart’s conclusions for OPTIMA. #asco26

[Tanja Spanic @TanjaSpanic]

Important results from Optima trail 💕⬇️

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌First results from the OPTIMA phase Ill randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
✨Robert C. Stein at #ASCO26
🔗 OPTIMA demonstrates that the 50-gene Prosigna test identifies a group of about 2/3 of patients with ER-positive HER2-negative early breast cancer who do not have a meaningful chance of benefit from adjuvant chemotherapy.
@OncoAlert #OncoAlertAF #BreastCancer